Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Ovarian epithelial cancer
Stage/Subtype:  recurrent ovarian epithelial cancer
Trial Type:  Treatment
Results 1-25 of 128 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and/or Bevacizumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Not yet active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY009, NCI-2016-01081, NCT02839707
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8109-002, NCI-2011-00940, EC-FV-06, NCT01170650
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR100983, NCI-2013-01419, 2012-004808-34, ET743OVC3006, NCT01846611
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PM1183-C-004-14, NCI-2015-01497, NCT02421588
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PR-30-5017-C, NCI-2016-00574, NCT02655016
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991009, NCI-2016-01427, 2015-003091-77, JAVELIN OVARIAN 200, NCT02580058
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8329, NCI-2011-00312, 09-000742, CDR0000657976, MAYO-MC0861, MC0861, NCT01012817
Vaccine Therapy in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC29810, NCI-2011-00285, NCT01312389
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Pegylated Liposomal Doxorubicin Hydrochloride and Nintedanib in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, Fallopian Tube, or Recurrent Metastatic Endometrial Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN10-149, NCI-2012-02106, 1103-09, 1011004095, NCT01485874
Fenretinide/Fenretinide Lipid Matrix and Ketoconazole in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SPOC-2011-001, NCI-2012-00354, NCT01550692, NCT01535157
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP-0011-001, NCI-2015-00728, 230612, NCT01567891
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Paclitaxel and Vascular-Targeting Gene Therapeutic VB-111 in Treating Patients with Recurrent Uterine, Ovarian, or Fallopian Tube Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 19
Trial IDs: 11-418, NCI-2013-00628, VB-111-157, NCT01801215, NCT01711970
GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Paclitaxel and Ganetespib in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN-064, NCI-2013-01416, NCT01962948
Talazoparib in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9510, NCI-2013-02371, P131220, 09-25-0099, 140015, P9510_A08PAMDREVW01, 14-C-0015, NCT01989546
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARN-AR18-CT-101, NCI-2016-00136, NCT02052128
Start Over